• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Intra-articular Transfer of Genes has Therapeutic Potential in Inflammatory Arthritis

Intra-articular Transfer of Genes has Therapeutic Potential in Inflammatory Arthritis

October 14, 2005 By Arthritis Center

The robust expression of pro-inflammatory cytokines by synovial macrophages and fibroblasts in RA and the relative ease of access of most affected joints make intra-articular gene therapy a compelling therapeutic possibility. Advantages include the ability to target only affected joints, reasonable assurance of delivery of therapy, and, potentially, the avoidance of adverse effects associated with systemic administration of immunomodulating therapies. In animal models of inflammatory arthritis, gene delivery of anti-inflammatory encoding genes has shown therapeutic potential. Here, Evans et al (PNAS 2005; 102:8698) report the first experience of the feasibility and safety of transfer of functioning gene products to human joints.

Methods

Synovial fibroblasts were harvested from 9 postmenopausal women with advanced RA who were scheduled for sialastic arthroplasty of metacarpal-phalangeal (MCP) joints 2-5. Harvested synovial fibroblasts were cultured and divided into two groups for each donor. Half of the cultured fibroblasts were transduced with a retrovirus engineered with a coding sequence for human IL-1 receptor antagonist (IL-1Ra), an anti-inflammatory cytokine and antagonist of the pro-inflammatory cytokine IL-1. The other half of the cultured fibroblasts were used as non-transduced controls. After ensuring that the transduced synovial fibroblasts were capable of secreting IL-1-Ra, the control and transduced cells were injected back into the MCP joints of the donor (2 joints each, performed in a double-blind fashion) 1 week prior to MCP arthroplasty. The 9 patients were evenly allocated to receive low, intermediate, or high doses of transduced cells (or non-transduced control). At arthroplasty, the synovial tissue was retrieved and expression of IL-1Ra was examined by qualitative and quantitative methods.

Results

The nine participants were all Caucasian women, 51 to 73 years of age, with longstanding destructive RA (10 to 26 years duration). 8 of the 9 were receiving DMARD therapy. 5 of the 9 were receiving corticosteroids.

Upon retrieval of synovium, all of the joints injected with transduced fibroblasts demonstrated expression of transgenic mRNA, while only one of the control joints demonstrated transgene expression (in a patient who had received high dose injection of transduced cells into 2 other MCP joints). IL-1Ra expression was dose dependent, with the 3 patients receiving the lowest dose of transduced cells demonstrating little IL-1Ra expression. In situ hybridization and immunohistochemistry revealed surface clusters of IL-1Ra expressing cells in the synovia of joints injected with transduced cells. These surface clusters were not seen in joints injected with non-transduced cells.

No immediate or long-term (greater than 5 years) safety issues were reported associated with the gene transfer experiment.

Conclusion

Intra-articular transfer of genes capable of expressing anti-inflammatory cytokine products is feasible and appears to be safe.

Editorial Comment

This work is a novel and extraordinary first step into an unexplored area of therapeutic potential in inflammatory arthritis. Owing to its novelty, the authors were appropriately cautious in the design of this study and utilized a clever set of methods in which the patients were exposed to their own transduced fibroblasts and only for a very short time period. Accordingly, as this is a phase 1 study, no conclusions can be drawn about the efficacy of the intervention.

Even so, a few concerns may already be raised from these results. Either by unintentional inoculation, measurement error, or by migration between joints, transgene expression was measured in a joint not thought to have been inoculated with transduced cells. This may represent the potential for genetic material introduced into a joint to exhibit effects in remote areas. This may be problematic when envisioning scenarios in which high concentrations of genetic material may be required (i.e. gene transfer to an inflamed knee). Additional study is required to examine the potential for transduced genetic material to migrate throughout the body.

Indeed, RA may not prove to be the ideal disorder for this type of intervention. The large number of joints involved, the small size of some of the joints involved and difficulty in reliably delivering agents into small joints may be impractical for RA patients and practitioners. However, inflammatory arthropathies with fewer numbers of joints involved (i.e. the seronegative spondyloarthropaties) may truly benefit from this type of intervention in the future.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy